Core concepts: Biosimilars

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 50, 2015, Pages 15261-15262

  Ornes, Stephen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; FILGRASTIM; GENERIC DRUG; TRASTUZUMAB;

BREAST CANCER; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; NOTE; PRIORITY JOURNAL; DRUG APPROVAL; ECONOMICS; HUMAN;

BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; DRUGS, GENERIC; HUMANS;

EID: 84950327388     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1520698112     Document Type: Note

References (2)

1. Grabowski H, Guha R, Salgado M (2014) Biosimilar competition: Lessons from Europe. Nat Rev Drug Discov 13(2):99-100.
2. Mulcahy AW, Predmore Z, Mattke S (2014) The Cost Savings Potential of Biosimilar Drugs in the United States. (Rand Corporation, Santa Monica, CA).